May 25, 2006 — Three new studies presented here at the 2006 annual meeting of the American Urological Association support the use of phosphodiesterase-5 (PDE-5) inhibitors for the resolution of lower ...

Boston, MA — December 18, 2025 — A research-driven evaluation assessing the comparative effectiveness of phosphodiesterase type 5 (PDE5) inhibitors is contributing to ongoing clinical discourse around ...

This article was reviewed by Martin Miner, MD. Cialis, which contains the active ingredient tadalafil, is one of the most popular medications for ED. It belongs to a class of drugs known as ...

Men with primary organic erectile dysfunction (ED) are less likely than those with primary psychogenic ED to adhere to treatment with PDE5 inhibitors. Men with primary organic erectile dysfunction (ED ...

To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...

Urologic surgeon Jose M. Flores, MD is lead author of a new study investigating the risk of biochemical recurrence after radical prostatectomy when taking ED drugs. There have been conflicting studies ...

PASADENA, Calif.--(BUSINESS WIRE)--25 years after Viagra hit the market, a group of experts from across the country examined the link between erectile dysfunction (ED) and heart health. Their summary ...

For men with a history of myocardial infarction or PCI, it may be risky to use nitrates for angina and phosphodiesterase-5 (PDE5) inhibitors for erectile dysfunction at the same time, a large Swedish ...